Key result
Low-dose acetylsalicylic acid, but not dazoxiben, provided complete relief of erythromelalgia and normalized platelet mean life span to 7.9 days in primary thrombocythaemia.
Why the study?
Does low dose acetylsalicylic acid relieve erythromelalgia in patients with primary thrombocythaemia?
Population
Patients with primary thrombocythaemia and erythromelalgia
Design
Case_series
Follow-up
10 days for dazoxiben, unspecified for subsequent…
Authors
Loading...
May support aspirin for erythromelalgia relief in primary thrombocythaemia; hypothesis-generating for cyclooxygenase involvement and needs prospective validation.
Observational
Does low dose acetylsalicylic acid relieve erythromelalgia in patients with primary thrombocythaemia?
Low-dose acetylsalicylic acid, but not dazoxiben, relieves erythromelalgia in primary thrombocythaemia, suggesting prostaglandin cyclooxygenase products are involved in its pathogenesis.
Michiels et al. (1993) conducted an observational in Erythromelalgia in primary thrombocythaemia. Dazoxiben and low-dose acetylsalicylic acid was evaluated on Relief of erythromelalgia and platelet mean life span. Low-dose acetylsalicylic acid, but not dazoxiben, provided complete relief of erythromelalgia and normalized platelet mean life span to 7.9 days in primary thrombocythaemia.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: